2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
17
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Neoplasm Metastasis
6
Prostatic Neoplasms
5
Melanoma
5
Lung Neoplasms
5
Solid Tumor
3
Pain, Postoperative
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Stromal Tumors
3
Colorectal Neoplasms
3
Anxiety Disorders
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Pain
2
Glioma
2
Colonic Neoplasms
2
Choledocholithiasis
2
Choledochal Cyst
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Interventions
Doxorubicin
6
Ifosfamide
5
Radiotherapy
4
pazopanib
3
cediranib
3
atezolizumab
3
Sunitinib
3
selinexor
2
perifosine
2
pembrolizumab
2
Trabectedin
2
Specimen Handling
2
Loperamide
2
Gemcitabine
2
Filgrastim
2
Dacarbazine
2
Cisplatin
2
Biopsy
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
spartalizumab
1
sargramostim
1
romidepsin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ixazomib
1
indolepropanol phosphate
1
futibatinib
1
fludarabine
1
cabozantinib
1
brostallicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Alveolar Soft Part
×
Midazolam
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled